154 related articles for article (PubMed ID: 19017546)
1. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
Caporali R; Pallavicini FB; Filippini M; Gorla R; Marchesoni A; Favalli EG; Sarzi-Puttini P; Atzeni F; Montecucco C
Autoimmun Rev; 2009 Jan; 8(3):274-80. PubMed ID: 19017546
[TBL] [Abstract][Full Text] [Related]
2. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry.
Caporali R; Sarzi-Puttini P; Atzeni F; Gorla R; Filippini M; Marchesoni A; Favalli EG; Bobbio-Pallavicini F; Montecucco C
Autoimmun Rev; 2010 Apr; 9(6):465-9. PubMed ID: 20044040
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of tumor necrosis factor for rheumatoid arthritis.
Moreland LW
J Rheumatol Suppl; 1999 May; 57():7-15. PubMed ID: 10328137
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients.
Watanabe T; Tanigawa T; Shiba M; Nadatani Y; Nagami Y; Sugimori S; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Koike T; Arakawa T
Gut; 2014 Mar; 63(3):409-14. PubMed ID: 23697473
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
Marchesoni A; Zaccara E; Gorla R; Bazzani C; Sarzi-Puttini P; Atzeni F; Caporali R; Bobbio-Pallavicini F; Favalli EG
Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
[TBL] [Abstract][Full Text] [Related]
9. [Anti-TNF alpha in rheumatoid arthritis].
Schreiber S; Sternon J
Rev Med Brux; 2001 Jun; 22(3):174-80. PubMed ID: 11488086
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ; van de Putte LB; Breedveld FC
Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
[TBL] [Abstract][Full Text] [Related]
11. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
12. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
[TBL] [Abstract][Full Text] [Related]
13. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.
Bullano MF; McNeeley BJ; Yu YF; Quimbo R; Burawski LP; Yu EB; Woolley JM
Manag Care Interface; 2006 Sep; 19(9):47-53. PubMed ID: 17017313
[TBL] [Abstract][Full Text] [Related]
14. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.
Favalli EG; Desiati F; Atzeni F; Sarzi-Puttini P; Caporali R; Pallavicini FB; Gorla R; Filippini M; Marchesoni A
Autoimmun Rev; 2009 Jan; 8(3):266-73. PubMed ID: 19022409
[TBL] [Abstract][Full Text] [Related]
15. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha-targeted therapy in rheumatoid arthritis.
Wendling D; Toussirot E
Rev Rhum Engl Ed; 1999 Apr; 66(4):187-91. PubMed ID: 10339773
[No Abstract] [Full Text] [Related]
18. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Cairns AP; Taggart AJ
Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes.
Bazzani C; Filippini M; Caporali R; Bobbio-Pallavicini F; Favalli EG; Marchesoni A; Atzeni F; Sarzi-Puttini P; Gorla R
Autoimmun Rev; 2009 Jan; 8(3):260-5. PubMed ID: 19027090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
